Lessons learned from molecular scaffold analysis

Journal of Chemical Information and Modeling

Volumn 51, Issue 8, 2011, Pages 1742-1753

  Hu, Ye ^a   Stumpfe, Dagmar ^a   Bajorath, Jürgen ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMISTRY;

BIOACTIVE COMPOUNDS; CHEMICAL COMPLEXITY; G-PROTEIN COUPLED RECEPTORS; ION CHANNEL; MOLECULAR ORGANIZATION; MOLECULAR SCAFFOLDS; MULTI-TARGETS; SMALL MOLECULES;

CHEMICAL ENGINEERING;

PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ARTICLE; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR LIBRARY; STATISTICS;

CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SMALL MOLECULE LIBRARIES;

EID: 80052002666     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci200179y     Document Type: Article

References (71)

1. Brown, N.; Jacoby, E. On scaffolds and hopping in medicinal chemistry Mini-Rev. Med. Chem. 2006, 6, 1217-1229 (Pubitemid 44697101)
2. Schneider, G.; Neidhart, W.; Giller, T.; Schmid, G. Scaffold-hopping by topological pharmacophore search: A contribution to virtual screening Angew. Chem., Int. Ed. 1999, 19, 2894-2896 (Pubitemid 29479958)
3. Geppert, H.; Vogt, M.; Bajorath, J. Current trends in ligand-based virtual screening: molecular representations, data mining methods, new application areas, and performance evaluation J. Chem. Inf. Model. 2010, 50, 205-216
4. Merlot, C.; Domine, D.; Cleva, C.; Church, D. J. Chemical substructures in drug discovery Drug Discovery Today 2003, 8, 594-602 (Pubitemid 36875723)
5. Oprea, T.; Davis, A.; Teague, S.; Leeson, P. Is there a difference between leads and drugs? A historical perspective J. Chem. Inf. Comput. Sci. 2001, 41, 1308
6. Clark, M. Generalized fragment-substructure based property prediction method J. Chem. Inf. Model 2005, 45, 30-38 (Pubitemid 40736953)
7. Lewell, X. Q.; Judd, D. B.; Watson, S. P.; Hann, M. M. RECAP-Retrosynthetic combinatorial analysis procedure: A powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry J. Chem. Inf. Comput. Sci. 1998, 38, 511-522 (Pubitemid 128594467)
8. Sutherland, J. J.; Higgs, R. E.; Watson, I.; Vieth, M. Chemical fragments as foundations for understanding target space and activity prediction J. Med. Chem. 2008, 51, 2689-2700 (Pubitemid 351620791)
9. Siegel, M. G.; Vieth, M. Drugs in other drugs: A new look at drugs as fragments Drug Discovery Today 2007, 12, 71-79 (Pubitemid 46014488)
10. Hajduk, P. J.; Greer, J. A decade of structure-based drug design: Strategic advances and lessons learned Nat. Rev. Drug Discovery 2007, 6, 211-219 (Pubitemid 46344625)
11. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery J. Med. Chem. 2008, 51, 3661-3680 (Pubitemid 351956496)
12. Graham, D. J.; Malarkey, C.; Schulmerich, M. V. Information content in organic molecules: Quantification and statistical structure via brownian processing J. Chem. Inf. Comput. Sci. 2004, 44, 1601-1611
13. Batista, J.; Bajorath, J. Mining of randomly generated molecular fragment populations uncovers activity-specific fragment hierarchies J. Chem. Inf. Model. 2007, 47, 1405-1413 (Pubitemid 47210044)
14. Bemis, G. W.; Murcko, M. A. The properties of known drugs. 1. Molecular frameworks J. Med. Chem. 1996, 39, 2887-2893 (Pubitemid 26251026)
15. Xu, Y.-J.; Johnson, M. Algorithm for naming molecular equivalence classes represented by labeled pseudographs J. Chem. Inf. Comput. Sci. 2001, 41, 181-185 (Pubitemid 33645688)
16. Katritzky, A. R.; Kiely, J. S.; Hebert, N.; Chassaing, C. Definition of templates within combinatorial libraries J. Comb. Chem. 2000, 2, 2-5
17. Schuffenhauer, A.; Ertl, P.; Roggo, S.; Wetzel, S.; Koch, M. A.; Waldmann, H. The scaffold tree-Visualization of the scaffold universe by hierarchical scaffold classification J. Chem. Inf. Model. 2007, 47, 47-58 (Pubitemid 46225559)
18. Liu, T.; Lin, Y.; Wen, X.; Jorissen, R. N.; Gilson, M. K. BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities Nucleic Acids Res. 2007, 35, D198-D201
19. ChEMBL. European Bioinformatics Institute (EBI): Cambridge, 2011. http://www.ebi.ac.uk/chembl/ (accessed May 2, 2011).
20. PubChem. National Center for Biotechnology Information: Bethesda, 2011. http://pubchem.ncbi.nlm.nih.gov/ (accessed May 2, 2011).
21. Broughton, H. B.; Watson, I. A. Selection of heterocycles for drug design J. Mol. Graph. Modell. 2004, 23, 51-58 (Pubitemid 39141245)
22. Wilkens, S. J.; Janes, J.; Su, A. I. HierS: Hierarchical scaffold clustering using topological chemical graphs J. Med. Chem. 2005, 48, 182-193
23. Wang, J.; Hou, T. Drug and drug candidate building block analysis J. Chem. Inf. Model 2010, 50, 55-67
24. Hu, Y.; Bajorath, J. Scaffold distributions in bioactive molecules, clinical trials compounds, and drugs ChemMedChem 2010, 5, 187-190
25. A., H.; Yuan, Q.; Lucas, K. A.; Funk, S. A.; Bartelt, W. F., III; Schenck, R. J.; Trippe, A. J. Structural diversity of organic chemistry. A scaffold analysis of the CAS registry J. Org. Chem. 2008, 73, 4443-4451 Lipkushttp://pubs.acs.org/doi/abs/10.1021/jo8001276 (Pubitemid 351842458)
26. Krier, M.; Bret, G.; Rognan, D. Assessing the scaffold diversity of screening libraries J. Chem. Inf. Model. 2006, 46, 512-524
27. Shelat, A. A.; Guy, R. K. Scaffold composition and biological relevance of screening libraries Nat. Chem. Biol. 2007, 3, 442-446 (Pubitemid 47080378)
28. Koch, M. A.; Schuffenhauer, A.; Scheck, M.; Wetzel, S.; Casaulta, M.; Odermatt, A.; Ertl, P.; Waldmann, H. Charting biologically relevant chemical space: A structural classification of natural products (SCONP) Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 17272-17277 (Pubitemid 41740856)
29. Schreiber, S. L. Target-oriented and diversity-oriented organic synthesis in drug discovery Science 2000, 287, 1964-1969 (Pubitemid 30158663)
30. Tan, D. S. Diversity-oriented synthesis: Exploring the intersections between chemistry and biology Nat. Chem. Biol. 1, 2005, 74-84
31. Ertl, P.; Jelfs, S.; Mühlbacher, J.; Schuffenhauer, A.; Selzer, P. Quest for the rings. In silico exploration of ring universe to identify novel bioactive heteroaromatic scaffolds J. Med. Chem. 2006, 49, 4568-4573 (Pubitemid 44162682)
32. Pollock, S. N.; Coutsias, E. A.; Wester, M. J.; Oprea, T. I. Scaffold topologies 1. Exhaustive enumeration up to eight rings J. Chem. Inf. Model. 2008, 48, 1304-1310
33. Wester, M. J.; Pollock, S. N.; Coutsias, E. A.; Allu, T. K.; Muresan, S.; Oprea, T. I. Scaffold topologies 2. Analysis of chemical databases J. Chem. Inf. Model. 2008, 48, 1304-1310
34. Pitt, W. R.; Parry, D. M.; Perry, B. G.; Groom, C. R. Heteroaromatic rings of the future J. Med. Chem. 2009, 52, 2952-2963
35. Blum, L. C.; Reymond, J.-L. 970 Million druglike small molecules for virtual screening in the chemical universe database GDB-13 J. Am. Chem. Soc. 2009, 131, 8732-8733
36. Evans, B. E.; Rittle, K. E.; Bock, M. G.; Dipardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists J. Med. Chem. 1988, 31, 2235-2246 (Pubitemid 19001640)
37. Müller, G. Medicinal chemistry of target family-directed masterkeys Drug Discovery Today 2003, 8, 681-691 (Pubitemid 36969999)
38. Constantino, L.; Barlocco, D. Privileged substructures as leads in medicinal chemistry Curr. Med. Chem. 2006, 13, 65-85
39. Klabunde, T.; Hessler, G. Drug design strategies for targeting G-protein-coupled receptors ChemBioChem 2002, 3, 928-944 (Pubitemid 35189597)
40. Aronov, A. M.; McClain, B.; Moody, C. S.; Murcko, M. A. Kinase-likeness and kinase-privileged fragments: Toward virtual polypharmacology J. Med. Chem. 2008, 51, 1214-1222 (Pubitemid 351480383)
41. Schnur, D. M.; Hermsmeier, M. A.; Tebben, A. J. Are target-family- privileged substructures truly privileged? J. Med. Chem. 2006, 49, 2000-2009
42. Hu, Y.; Wassermann, A. M.; Lounkine, E.; Bajorath, J. Systematic analysis of public domain compound potency data identifies selective molecular scaffolds across druggable target families J. Med. Chem. 2010, 53, 752-758
43. Hu, Y.; Bajorath, J. Exploring target-selectivity patterns of molecular Scaffolds ACS Med. Chem. Lett. 2010, 1, 54-58
44. Mestres, J.; Gregori-Puigjané, E.; Valverde, S.; Solé, R. V. Data completeness: The Achilles heel of drug-target networks Nat. Biotechnol. 2008, 26, 983-984
45. Paolini, G. V.; Shapland, R. H. B.; van Hoorn, W. P.; Mason, J. S.; Hopkins, A. L. Global mapping of pharmacological space Nat. Biotechnol. 2006, 24, 805-815 (Pubitemid 44086621)
46. Keiser, M. J.; Roth, B. L.; Armbruster, B. N.; Ernsberger, P.; Irwin, J. J.; Shoichet, B. K. Relating protein pharmacology by ligand chemistry Nat. Biotechnol. 2007, 25, 197-206 (Pubitemid 46227119)
47. Morphy, R. Selectively nonselective kinase inhibition: Striking the right balance J. Med. Chem. 2010, 53, 1413-1437
48. Hopkins, A. L. Network pharmacology: The next paradigm in drug Discovery Nat. Chem. Biol. 2008, 4, 682-690
49. Metz, J. A.; Hajduk, P. J. Rational approaches to targeted polypharmacology: Creating and navigating protein-ligand interaction networks Curr. Opin. Chem. Biol. 2010, 14, 498-504
50. Keiser, M. J.; Irwin, J. J.; Shoichet, B. K. The chemical basis of pharmacology Biochemistry 2010, 49, 10267-10276
51. Chen, B.; Wild, D.; Guha, R. PubChem as a source of polypharmacology J. Chem. Inf. Model 2009, 49, 2044-2055
52. Cases, M.; Mestres, J. A. Chemogenomic approach to drug discovery: Focus on cardiovascular diseases Drug Discovery Today 2009, 14, 479-485
53. Hu, Y.; Bajorath, J. Polipharmacology directed data mining: Identification of Promiscuous chemotypes with different activity profiles and comparison to approved drugs J. Chem. Inf. Model. 2010, 50, 2112-2118
54. Hu, Y.; Bajorath, J. Global assessment of scaffold hopping potential for current pharmaceutical target. Med Chem. Commun. 2010, 1, 339-344
55. Hu, Y.; Bajorath, J. Structural and potency relationships between scaffolds of compounds active against human targets ChemMedChem 2010, 5, 1681-1685
56. Irwin, J. J.; Shoichet, B. K. ZINC-A free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 2005, 45, 177-182 (Pubitemid 40736970)
57. Xu, Y.-J.; Johnson, M. Using molecular equivalence numbers to visually explore structural features that distinguish chemical libraries J. Chem. Inf. Comput. Sci. 2002, 42, 912-926 (Pubitemid 35355241)
58. Koch, M. A.; Schuffenhauer, A.; Scheck, M.; Wetzel, S.; Casaulta, M.; Odermatt, A.; Ertl, P.; Waldmann, H. Charting biologically relevant chemical space: A structural classification of natural products (SCONP) Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17272-17277 (Pubitemid 41740856)
59. Wetzel, S.; Klein, K.; Renner, S.; Rauh, D.; Oprea, T. I.; Mutzel, P.; Waldmann, H. Interactive exploration of chemical space with scaffold hunter Nat. Chem. Biol. 2009, 5, 581-583
60. Renner, S.; van Otterlo, W. A. L.; Seoane, M. D.; Möcklinghoff, S.; Hofmann, B.; Wetzel, S.; Schuffenhauer, A.; Ertl, P.; Oprea, T. I.; Steinhilber, D.; Brunsveld, L.; Rauh, D.; Waldmann, H. Bioactivity-guided mapping and navigation of chemical space Nat. Chem. Biol. 2009, 5, 585-592
61. Wetzel, S.; Wilk, W.; Chammaa, S.; Sperl, B.; Roth, A. G.; Yektaoglu, A.; Renner, S.; Berg, T.; Arenz, A.; Giannis, A.; Oprea, T. I.; Rauh, D.; Kaiser, M.; Waldmann, H. A scaffold-tree-merging strategy for prospective bioactivity annotation of γ-pyrones Angew. Chem. 2010, 122, 3748-3752
62. Varin, T.; Gubler, H.; Parker, C. N.; Zhang, J.-H.; Raman, P.; Ertl, P.; Schuffenhauer, A. Compound set enrichment: A novel approach to analysis of primary HTS data J. Chem. Inf. Model. 2010, 50, 2067-2078
63. Hu, Y.; Bajorath, J. Combining horizontal and vertical substructure relationships in scaffold hierarchies for activity prediction J. Chem. Inf. Model. 2011, 51, 248-257
64. Varin, T.; Schuffenhauer, A.; Ertl, P.; Renner, S. Mining for bioactive scaffolds with scaffold networks: Improved compound set enrichment from primary screening data J. Chem. Inf. Model. 2011, 51, 1528-1538
65. Maggiora, G. M. On outliers and activity cliffs-Why QSAR often disappoints J. Chem. Inf. Model, 2006, 46, 1535 (Pubitemid 44185680)
66. Wassermann, A. M.; Wawer, M.; Bajorath, J. Activity landscape representations for structure-activity relationship analysis J. Med. Chem. 2010, 53, 8209-8223
67. Hu, Y.; Bajorath, J. Molecular scaffolds with high propensity to form multi-target activity cliffs J. Chem. Inf. Model 2010, 50, 500-510
68. Salaski, E. J.; Krishnamurthy, G.; Ding, W.-D.; Yu, K.; Insaf, S. S.; Eid, C.; Shim, J.; Levin, J. L.; Tabei, K.; Toral-Barza, L.; Zhang, W.-G.; McDonald, L. A.; Honores, E.; Hanna, C.; Yamashita, A.; Johnson, B.; Li, Z.; Laakso, L.; Powell, D.; Mansour, T. S. Pyranonaphthoquinone lactones: A new class of AKT selective kinase inhibitors alkylate a regulatory loop cysteine J. Med. Chem. 2009, 52, 2181-2184
69. Yan, A.; Wang, L.; Xu, S.; Xu, J. Aurora-A kinase inhibitor scaffolds and binding modes Drug Discovery Today 2011, 16, 5-6
70. Kinase Inhibitor Database http://www.gvkbio.com/database-pdf/Kinase- Inhibitor.pdf (assessed April 4, 2011).
71. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N. S.; Wang, J. T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software environment for integrated models of biomolecular interaction networks Genome Res. 2003, 13, 2498-2504 (Pubitemid 37428274)